Bendamustine in combination with rituximab for previously untreated patients with chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group.

@article{Fischer2012BendamustineIC,
  title={Bendamustine in combination with rituximab for previously untreated patients with chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group.},
  author={Kirsten J Fischer and Paula Cramer and Raymonde M Busch and Sebastian Boettcher and Jasmin Bahlo and J{\"o}erg Schubert and Karl H Pfl{\"u}ger and Silke Schott and Valentin Goede and Susanne Isfort and Julia von Tresckow and Anna-Maria Fink and Andreas B{\"u}hler and Dirk Winkler and K S Kreuzer and Peter Anton Staib and Matthias Ritgen and Michael Kneba and Hartmut D{\"o}hner and Barbara F Eichhorst and Michael J Hallek and Stephan Stilgenbauer and C M Wendtner},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2012},
  volume={30 26},
  pages={3209-16}
}
PURPOSE We investigated the safety and efficacy of bendamustine and rituximab (BR) in previously untreated patients with chronic lymphocytic leukemia (CLL). PATIENTS AND METHODS In all, 117 patients, age 34 to 78 years, 46.2% of patients at Binet stage C, and 25.6% of patients age 70 years or older received BR chemoimmunotherapy for first-line treatment of CLL. Bendamustine was administered at a dose of 90 mg/m(2) on days 1 and 2 combined with 375 mg/m(2) rituximab on day 0 of the first… CONTINUE READING
Highly Influential
This paper has highly influenced a number of papers. REVIEW HIGHLY INFLUENTIAL CITATIONS